Study Title
MetMED: Phase III randomized double-blind placebo-controlled trial of metformin for cognitive recovery and white matter growth in paediatric medulloblastoma patients
Protocol ID
MetMED
Disease (Sub Disease)
Medulloblastoma
Diagnosis Stage
Previously treated
Location
NSW, VIC, WA
Sponsor
Australian and New Zealand Children's Haematology Oncology Group
Collaborators
Hospital for Sick Kids, Toronto
Links
Trial Status
Open
Sites
Monash Children's Hospital
Royal Children's Hospital
John Hunter Children's Hospital
Perth Children's Hospital
Royal Children's Hospital
John Hunter Children's Hospital
Perth Children's Hospital
Study Type
Treatment
Phase
Phase 3
Age Eligibility
7 years to 17 years
ANZCTR
ACTRN12622000045718
| Study Title | MetMED: Phase III randomized double-blind placebo-controlled trial of metformin for cognitive recovery and white matter growth in paediatric medulloblastoma patients |
|---|---|
| Protocol ID | MetMED |
| Disease (Sub Disease) | Medulloblastoma |
| Diagnosis Stage | Previously treated |
| Location | NSW / VIC / WA |
| Sponsor | Australian and New Zealand Children's Haematology Oncology Group |
| Collaborators | Hospital for Sick Kids, Toronto |
| Links | https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=381003&isReview=true |
| Trial Status | Open |
| Trial Open Date | 28/09/2022 |
| Sites | Monash Children's Hospital/ Royal Children's Hospital / John Hunter Children's Hospital/ Perth Children's Hospital/ |
| Study Type | Treatment |
| Phase | Phase 3 |
| Age Eligibility | 7 years to 17 years |
| ANZCTR | ACTRN12622000045718 |